Literature DB >> 29169629

Suppurative Inflammation and Local Tissue Destruction Reduce the Penetration of Cefuroxime to Infected Bone Implant Cavities.

L Kruse Jensen1, J Koch2, N Lind Henriksen2, Mats Bue3, M Tøttrup4, P Hanberg5, K Søballe5, H Elvang Jensen2.   

Abstract

Treatment of post-traumatic and implant-associated osteomyelitis (IAO) includes surgical debridement, removal of implants and long-term antibiotic therapy. The success of antibiotic therapy relies not only on activity towards the infecting pathogen, but also on sufficient penetration of the target site. The aim of the present study was to characterize the local pathological changes associated with reduced penetration of cefuroxime to infected bone implant cavities. Previously, reduced penetration of systemically administrated cefuroxime was demonstrated in the implant cavity of 10 pigs with Staphylococcus aureus IAO present for 5 days. In the present study, a comprehensive histopathological characterization of the peri-implant bone tissue was performed and correlated with the reduced penetration of cefuroxime. In two pigs, the levels of oxygen, pyruvate and lactate was estimated in the implant cavity. A peri-implant pathological bone area (PIBA) developed with a width of 1.2 up to 3.8 mm. PIBAs included: (1) suppuration, resulting in destruction of the implant cavity contour, and (2) a non-vascular zone of primarily necrotic bone tissue. A strong negative correlation was seen between PIBA width and cefuroxime area under the concentration time curves (AUC[0-last]) and peak concentration of cefuroxime (Cmax). All metabolic measurements demonstrated hypoxia. In conclusion, subacute suppurative bone inflammation with local tissue destruction can result in decreased penetration of antibiotics and insufficient oxygen supply.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  antibiotic treatment; bone; inflammation; porcine model

Mesh:

Substances:

Year:  2017        PMID: 29169629     DOI: 10.1016/j.jcpa.2017.10.001

Source DB:  PubMed          Journal:  J Comp Pathol        ISSN: 0021-9975            Impact factor:   1.311


  6 in total

1.  In Vivo Gentamicin Susceptibility Test for Prevention of Bacterial Biofilms in Bone Tissue and on Implants.

Authors:  Louise Kruse Jensen; Thomas Bjarnsholt; Kasper N Kragh; Bent Aalbæk; Nicole Lind Henriksen; Sophie Amalie Blirup; Karen Pankoke; Andreas Petersen; Henrik Elvang Jensen
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

2.  Vancomycin bone and tissue concentrations following tibial intraosseous administration - evaluated in a porcine model.

Authors:  Josephine Olsen Kipp; Pelle Hanberg; Josefine Slater; Line Møller Nielsen; Stig Storgaard Jakobsen; Maiken Stilling; Mats Bue
Journal:  J Bone Jt Infect       Date:  2021-02-12

3.  Fluorescent tetracycline bone labeling as an intraoperative tool to debride necrotic bone during septic hip revision: a preliminary case series.

Authors:  Ernesto Muñoz-Mahamud; Jenaro Ángel Fernández-Valencia; Andreu Combalia; Laura Morata; Álex Soriano
Journal:  J Bone Jt Infect       Date:  2021-01-27

4.  Inflammatory proteins in infected bone tissue - An explorative porcine study.

Authors:  Mats Bue; Natasja Leth Bergholt; Louise Kruse Jensen; Henrik Elvang Jensen; Kjeld Søballe; Maiken Stilling; Pelle Hanberg
Journal:  Bone Rep       Date:  2020-06-26

5.  Intermittent Short-Term Infusion vs. Continuous Infusion of Piperacillin: Steady State Concentrations in Porcine Cervical Spine Tissue Evaluated by Microdialysis.

Authors:  Elisabeth Krogsgaard Petersen; Pelle Hanberg; Martin Knudsen; Sara Kousgaard Tøstesen; Andrea René Jørgensen; Kristina Öbrink-Hansen; Kjeld Søballe; Maiken Stilling; Mats Bue
Journal:  Antibiotics (Basel)       Date:  2022-07-07

6.  Influence of sub-inhibitory concentrations of antimicrobials on micrococcal nuclease and biofilm formation in Staphylococcus aureus.

Authors:  Colin W K Rosman; Henny C van der Mei; Jelmer Sjollema
Journal:  Sci Rep       Date:  2021-06-24       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.